Detailed Mechanism of Action
GHK-Cu (Glycyl-L-Histidyl-L-Lysine:Copper) is a naturally occurring tripeptide-copper complex originally isolated from human plasma. This 100mg extended-supply vial contains double the standard dose, designed for longer research protocols requiring fewer reconstitutions. The compound's plasma concentration naturally declines with age — from approximately 200 ng/mL at age 20 to roughly 80 ng/mL by age 60 — and this decline is closely correlated with the progressive deterioration of skin quality, wound healing capacity, and tissue regeneration that characterizes biological aging.
The molecular mechanism of GHK-Cu is remarkably multifaceted. Its primary action is stimulation of collagen synthesis, specifically Types I and III collagen, with research demonstrating up to a 70% increase in collagen production. Beyond collagen, it enhances synthesis of decorin and glycosaminoglycans — structural components that provide the hydration matrix and mechanical resilience of skin tissue. GHK-Cu intelligently balances tissue remodeling by modulating both metalloproteinases (MMPs, which break down damaged tissue) and their inhibitors (TIMPs, which protect new tissue), facilitating controlled renewal rather than either excessive breakdown or uncontrolled accumulation.
Perhaps most remarkably, GHK-Cu affects the expression of over 4,000 genes, essentially resetting gene expression patterns toward a healthier configuration. This includes upregulating DNA repair genes, suppressing genes associated with metastasis and chronic inflammation, and increasing antioxidant enzyme production (particularly superoxide dismutase). The compound reduces TNF-alpha-induced IL-6 secretion in dermal fibroblasts, modulates the NF-kB inflammatory pathway, and actively recruits stem cells and immune cells to injury sites. The copper ion serves as both a structural component of the peptide complex and a cofactor for antioxidant enzymes, making it essential to the compound's biological activity.
Clinical Evidence
GHK-Cu has accumulated a substantial body of clinical evidence for skin rejuvenation applications. In controlled wrinkle reduction studies, GHK-Cu achieved a 31.6% reduction in wrinkle volume — outperforming Matrixyl 3000, one of the cosmetic industry's most widely used peptide ingredients. A separate controlled study documented 55.8% wrinkle volume reduction and 32.8% wrinkle depth reduction compared to control subjects, accompanied by measurable improvements in skin firmness, elasticity, and optical clarity. These are not superficial hydration effects but genuine structural improvements reflecting new collagen deposition and matrix remodeling.
The timeline for observable results is well-characterized: hydration improvements emerge within 1-2 weeks as glycosaminoglycan synthesis increases the skin's water-binding capacity. By 4-8 weeks, meaningful improvements in skin texture, firmness, and fine lines become apparent as new collagen fibers achieve structural significance. Increases in skin thickness and density — measurable by ultrasound — confirm the depth of these changes. In wound healing contexts, GHK-Cu accelerates wound contraction, increases granulation tissue formation, stimulates angiogenesis (new blood vessel growth), and enhances collagen and decorin gene expression in healing tissues.
Hair growth applications have also shown promise, with evidence of follicle size enlargement and stimulated growth in thinning areas. In a topical application study, one month of GHK-Cu cream produced significant collagen effects in 70% of female participants. While the FDA prohibited injectable GHK-Cu from commercial compounding in 2023, topical formulations remain available in cosmetics, and the compound continues to be accessible as a research peptide. The injectable route provides direct systemic delivery with a plasma half-life of approximately 30 minutes and approximately 95% rapid clearance.
Dosing Protocol
The 100mg extended-supply vial is designed for comprehensive research protocols requiring sustained GHK-Cu administration over multiple months. Standard injectable dosing uses 1-2 mg per injection, administered 2-3 times weekly. At 2mg three times per week, the 100mg vial provides approximately 16 weeks of research compound — sufficient for a complete 12-week cycle with additional supply for transitional dosing. Wellness protocols may use 0.5 mg daily (5 days per week), while wound healing protocols typically employ higher doses of 2-3 mg daily.
For reconstitution, the 100mg vial can be reconstituted with a larger volume of bacteriostatic water to create a practical working concentration. Adding 10mL of BAC water produces a 10mg/mL concentration — at 2mg per dose, each injection uses 0.2mL (20 units on a U-100 insulin syringe), providing 50 doses per vial. Alternatively, subjects may reconstitute partial amounts: draw 5mL of BAC water into half the vial for initial use, keeping the remaining lyophilized powder sealed for future reconstitution. Inject subcutaneously in the abdomen, thigh, or upper arm with systematic rotation.
GHK-Cu pairs well with other healing and anti-aging peptides. It is a component of both the BBG70 blend (BPC-157 + GHK-Cu + TB-500) and the KLOW blend (GHK-Cu + TB-500 + BPC-157 + KPV). For subjects who prefer single-compound protocols with precise dose control, the standalone 100mg vial offers the most cost-effective option for extended research. Cycle lengths typically run 4-12 weeks on, 2-4 weeks off. For research purposes only.
Side Effects & Safety
GHK-Cu is among the best-tolerated research peptides available, consistent with its status as a naturally occurring human compound. The body already produces and recognizes GHK-Cu, which contributes to its favorable safety profile. Injectable administration may cause mild, transient injection site reactions — temporary redness, slight swelling, or localized discomfort — that resolve within hours. These are consistent with any subcutaneous injection protocol rather than compound-specific effects.
The copper component requires consideration in specific populations. While the copper delivered by standard GHK-Cu doses is minimal relative to dietary copper intake (the recommended daily copper intake is 0.9mg, and each GHK-Cu injection delivers far less), individuals with Wilson's disease — a genetic condition causing pathological copper accumulation — must avoid copper-containing compounds. Subjects with known copper hypersensitivity should also exercise caution. The short plasma half-life (~30 minutes, ~95% rapid clearance) limits systemic copper exposure, but cumulative effects over very long high-dose protocols lack extensive characterization.
No serious adverse events have been attributed to GHK-Cu in published research. The compound does not affect hormonal systems, does not disrupt glucose metabolism, and carries none of the cardiovascular or metabolic concerns associated with GH-related peptides. It does not suppress or alter endogenous hormone production. Contraindications include known hypersensitivity, Wilson's disease, pregnancy, and breastfeeding. This product is for research purposes only.
Storage & Reconstitution
Store the lyophilized GHK-Cu 100mg vial at 2-8°C (36-46°F) before reconstitution. For extended storage of the sealed vial, -20°C is acceptable. The copper complex may be sensitive to photo-oxidation, making light protection particularly important — keep in original packaging or wrap in aluminum foil. The 100mg vial contains a larger quantity of lyophilized material, so dissolution may take slightly longer than smaller vials; allow adequate time for complete reconstitution.
Reconstitute with bacteriostatic water (0.9% benzyl alcohol). Swab both vial stoppers with alcohol. For the full 100mg vial, adding 10mL of BAC water creates a 10mg/mL solution. This is a practical concentration for standard 1-2mg doses. Inject BAC water slowly along the glass wall of the vial. Do not shake — gently swirl or roll between palms until all powder is dissolved. GHK-Cu solution typically shows a faint blue tint from the copper complex; this is expected and does not indicate degradation. The solution must be clear without visible particulates.
After reconstitution, store at 2-8°C and use within 28 days. Given the large vial size, consider whether the full quantity will be used within 28 days; if not, partial reconstitution may be preferable. Never freeze reconstituted GHK-Cu. In the UAE, where summer temperatures can exceed 45°C, strict cold chain management is essential. The copper-peptide complex is susceptible to heat-accelerated oxidation, making proper temperature control especially critical. Return the vial to the refrigerator immediately after each use. Use insulated bags for transport.
Frequently Asked Questions
What is GHK-Cu and how does it work?
GHK-Cu is a naturally occurring copper tripeptide (Gly-His-Lys:Copper) that declines with age. It stimulates collagen synthesis (up to 70% increase), affects 4,000+ genes toward healthier expression, enhances antioxidant defenses, recruits stem cells, reduces inflammation, and promotes tissue repair. It is one of the most comprehensively studied peptides for skin regeneration and anti-aging applications.
Why choose the 100mg vial over the 50mg?
The 100mg vial provides double the supply at a better cost-per-milligram ratio, ideal for extended protocols. At 2mg three times weekly, it supplies approximately 16 weeks of compound — enough for a complete 12-week cycle with margin. It reduces reconstitution frequency and provides consistent supply for serious multi-month research programs.
What results can be expected and when?
Hydration improvements: 1-2 weeks. Skin texture, firmness, and wrinkle improvement: 4-8 weeks. Clinical data shows 31.6% wrinkle volume reduction (superior to Matrixyl 3000), 55.8% wrinkle volume reduction versus control. Measurable increases in skin thickness and density occur with continued use.
How should GHK-Cu 100mg be dosed?
Standard: 1-2mg per injection, 2-3 times weekly, subcutaneously. Wellness: 0.5mg daily (5 days/week). Wound healing: 2-3mg daily. Cycle 4-12 weeks on, 2-4 weeks off. The 100mg vial reconstituted with 10mL BAC water = 10mg/mL; each 2mg dose = 0.2mL (20 units on U-100 syringe), providing 50 doses.
How should GHK-Cu be stored?
Store lyophilized vials at 2-8°C. After reconstitution, refrigerate and use within 28 days. Consider partial reconstitution if the full amount will not be used in 28 days. Solution may have a faint blue tint — this is normal. Never freeze. Maintain strict cold chain in the UAE, especially during summer.
Disclaimer: This product is sold for laboratory research purposes only. Not for human consumption. All information provided is for educational purposes and does not constitute medical advice. Consult a qualified healthcare provider before starting any peptide protocol.
